| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
This research aims to clarify of success factors of biotech companies through analysis of their drug pipelines and patent specifications, based on our prior findings of correlation between their patent productivities and business conditions, that is bankruptcy, continuing and M&A.
Our analysis shows that there is no correlation between the number of drug candidates and annual patent families. We found differences in partner of joint patent application and contents of claims between bankruptcy group and M&A group, although there was no difference in ratio of joint patent application, and number of applicants and inventors. While treatment method claim of bankruptcy group is significantly higher, claims of drug target and method of screening of M&A group were significantly higher. We discuss success factors from perspectives of an alliance and R&D strategy.
|
